Introduction
Behavior of Complex Systems in nature can be described mathematically by using phenotypic response surfaces. These integrate contributions of individual input factors and calculate respective system outputs. Precisely controlling all input factors drives the behavior of complex systems towards the desired outputs. Phenotypic response surfaces were originally developed to actively influence airflow around aircrafts. Arrays of sensors together with active microflaps could successfully be employed to control vortex generation and thereby improve flight characteristics.
Optim.AI™ is a functional precision medicine platform, that applies the same approach to treating cancer. The system input from 12 drugs is measured at three different concentrations ex vivo, and a proprietary AI predicts the functional response to >500’000 drug-dose combinations. Combination therapy selected with Optim.AI™ has successfully been administered to patients with acute myeloid leukemia (Cancer Med., 2024), soft tissue sarcoma (NPJ Precis. Oncol., 2025), and yielded increased Progression Free Survival over physician-selected treatment (HR 0.56 [95% CI, 0.3441 to 0.9092]) in patients with non-Hodgkin lymphoma (JCO Precision Oncology 2025). In this study, we evaluated the technical feasibility and potential clinical utility of Optim.AI™ in breast cancer using fresh tissues and patient-derived organoids (PDOs).
Poster Content:
-
Feasibility of leveraging Optim.AI™ to evaluate patient tumor sensitivity to systemic treatments.
-
Application of Optim.AI™ in metastatic ER+ PR+ breast cancer, a case report.
Conclusion:
This preliminary study demonstrates the feasibility of Optim.AI™ in guiding treatment options for breast cancer patients, and its potential application at multiple stages of therapy. Future prospective clinical concordance data would further validate Optim.AI’s predictive value and establish its utility in breast
Submit the form to get access to full poster.